委外研发机构市场规模、份额、成长分析（按类型、治疗领域、最终用户和地区）- 2025 年至 2032 年行业预测

2023 年全球委外研发机构市场规模价值 613 亿美元，预计将从 2024 年的 663.9 亿美元增长到 2032 年的 1256.4 亿美元，预测期内（2025-2032 年）的复合年增长率为 8.3%。

由于医疗保健外包趋势日益增强以及全球製造成本不断上升，委外研发机构(CRO) 市场预计将经历显着增长。预计对医学研究和临床试验的投资增加将增加 CRO 的商业机会。药物开发的复杂性将进一步增加对CRO的需求，使医疗保健提供者能够降低成本，同时提高盈利。此外，新兴市场良好的法规环境为业务扩展提供了新的途径。然而，他们面临着智慧财产权问题、对製药公司的依赖以及 CRO 之间的激烈竞争等挑战。整体而言，机会很多，但相关人员必须克服这些限制因素，才能充分利用市场的巨大潜力。

目录

介绍

• 调查目的
• 研究范围
• 定义

调查方法

• 资讯采购
• 二次资料和一次资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 细分机会分析

市场动态与展望

• 市场概览
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制与挑战
• 波特的分析

关键市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2024年）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 定价分析
• 监管格局
• 案例研究
• 技术分析

药物委外研发机构市场规模（按类型和复合年增长率）（2025-2032）

• 市场概览
• 药物研发
  • 目标检验
  • 线索识别
  • 先导药物最适化
  • 其他的
• 临床前
• 临床
  • 第一阶段试验服务
  • 第二阶段检测服务
  • III期临床试验服务
  • 第四阶段检测服务
• 其他的

委外研发机构市场规模（依治疗领域及复合年增长率）（2025-2032）

• 市场概览
• 肿瘤学
• 心臟病学
• 感染疾病
• 神经病学
• 免疫疾病
• 胃肠病学和肝病学
• 其他的

药物委外研发机构市场规模（按最终用户和复合年增长率） (2025-2032)

• 市场概览
• 製药和生物技术公司
• 医疗设备公司
• 其他的

药物委外研发机构市场规模（按地区）及复合年增长率（2025-2032）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 德国
  • 西班牙
  • 法国
  • 英国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲
• 中东和非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东和非洲地区

竞争资讯

• 前五大公司对比
• 主要企业市场定位（2024年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2024年）
• 主要企业简介
  • 公司详情
  • 产品系列分析
  • 公司分部份额分析
  • 收益与前一年同期比较对比（2022-2024 年）

主要企业简介

• IQVIA（USA）
• ICON plc（Ireland）
• Charles River Laboratories（USA）
• Medpace（USA）
• Fortrea（USA）
• Parexel（USA）
• Syneos Health（USA）
• Thermo Fisher Scientific（USA）
• PPD Inc.（USA）
• Labcorp Drug Development（USA）
• Eurofins Scientific（France）
• SGS SA（Switzerland）
• PSI CRO AG（Switzerland）
• Novotech（Australia）
• KCR SA（Poland）
• Linical Co., Ltd.（Japan）
• Pharmaron（China）
• WuXi AppTec（China）
• WuXi Biologics（China）
• Tigermed（China）

结论和建议

Global Contract Research Organization Market size was valued at USD 61.3 billion in 2023 and is poised to grow from USD 66.39 billion in 2024 to USD 125.64 billion by 2032, growing at a CAGR of 8.3% during the forecast period (2025-2032).

The contract research organization (CRO) market is poised for significant growth driven by the increasing trend of outsourcing in healthcare and surging global manufacturing costs. Investments in medical research and a rise in clinical trials are anticipated to enhance business opportunities for CROs. The intricate nature of drug development further fuels demand for these organizations, enabling healthcare providers to reduce costs while enhancing profitability. Additionally, favorable regulatory environments in emerging markets present new avenues for expansion. However, the market faces challenges from intellectual property concerns, reliance on pharmaceutical firms, and intense competition among CROs. Overall, while opportunities abound, stakeholders must navigate these restraints to capitalize on the market's promising potential.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Contract Research Organization market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Contract Research Organization Market Segments Analysis

Global Contract Research Organization Market is segmented by Type, Therapeutic Area, End-User and region. Based on Type, the market is segmented into Drug Discovery, Pre-Clinical, Clinical and Others. Based on Therapeutic Area, the market is segmented into Oncology, Cardiology, Infectious Disease, Neurology, Immunological Disorders, Gastroenterology and Hepatology and Others. Based on End-User, the market is segmented into Pharmaceutical and Biotechnological Companies, Medical Device Companies and Others. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Contract Research Organization Market

The global contract research organization (CRO) market is significantly driven by the rising trend of outsourcing within the healthcare sector, especially as the demands on healthcare systems continue to escalate. Pharmaceutical and biotechnology companies are increasingly turning to CROs for their clinical trials, drug development, and regulatory services. This strategic shift allows these companies to lower expenses, tap into specialized knowledge, and accelerate the process of bringing new products to market. As a result, the reliance on CROs is intensifying, fostering growth within the industry and enhancing collaborative opportunities between pharmaceutical firms and research organizations.

Restraints in the Global Contract Research Organization Market

As intellectual property rights tighten in the pharmaceutical and biotech sectors, companies may grow increasingly apprehensive about the security of their proprietary information when outsourcing to contract research organizations (CROs). This heightened concern over the protection of intellectual property could pose a significant challenge to the growth of the global CRO market. If companies perceive the risk of intellectual property theft or misuse to be too high, they may hesitate to engage with CROs, which can ultimately hinder market expansion and limit collaboration in research and development efforts within these industries in the foreseeable future.

Market Trends of the Global Contract Research Organization Market

The Global Contract Research Organization (CRO) market is witnessing a significant trend toward the integration of Artificial Intelligence (AI) and machine learning technologies. These advancements are revolutionizing clinical trial processes by enhancing trial design, optimizing patient recruitment, and streamlining data analysis, resulting in improved efficiency and accuracy. The increased adoption of AI enables CROs to automate various business functions, reducing operational costs and expediting project timelines. This technological shift is not only transforming how CROs operate but also enhancing the drug development pipeline, ultimately driving growth in the market as stakeholders seek innovative solutions for complex clinical challenges.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Drivers & Opportunities
  • Restraints & Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2024
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Regulatory Landscape
• Case Studies
• Technology Analysis

Global Contract Research Organization Market Size by Type & CAGR (2025-2032)

• Market Overview
• Drug Discovery
  • Target Validation
  • Lead Identification
  • Lead Optimization
  • Others
• Pre-Clinical
• Clinical
  • Phase I Trial Services
  • Phase II Trial Services
  • Phase III Trial Services
  • Phase IV Trial Services
• Others

Global Contract Research Organization Market Size by Therapeutic Area & CAGR (2025-2032)

• Market Overview
• Oncology
• Cardiology
• Infectious Disease
• Neurology
• Immunological Disorders
• Gastroenterology and Hepatology
• Others

Global Contract Research Organization Market Size by End-User & CAGR (2025-2032)

• Market Overview
• Pharmaceutical and Biotechnological Companies
• Medical Device Companies
• Others

Global Contract Research Organization Market Size & CAGR (2025-2032)

• North America (Type, Therapeutic Area, End-User)
  • US
  • Canada
• Europe (Type, Therapeutic Area, End-User)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Type, Therapeutic Area, End-User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Type, Therapeutic Area, End-User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Type, Therapeutic Area, End-User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2024
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2024
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2022-2024)

Key Company Profiles

• IQVIA (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• ICON plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Charles River Laboratories (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medpace (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fortrea (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Parexel (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Syneos Health (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Thermo Fisher Scientific (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PPD Inc. (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Labcorp Drug Development (USA)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Eurofins Scientific (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SGS SA (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• PSI CRO AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novotech (Australia)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• KCR S.A. (Poland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Linical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pharmaron (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi AppTec (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• WuXi Biologics (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Tigermed (China)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations